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Human T-cell leukemia virus type I (HTLV-I) is a retrovirus that causes adult T-
cell leukemia. The male-to-female transmission is stronger than the reverse, so the 
carrier proportion of women is greater than that of men. On the other hand, since 
the mother-to-child transmission route via the breast-feeding is common for baby 
boys and girls, it has been thought the HTLV-I proportions of boys and girls are 
the same until now. A question arises as to whether the ‘innate protection powers 
against human virus’ are the same between baby boys and girls. We utilize Blood 
donor data in 1995-1998, which were provided by Japan Red Cross Society of Oita, 
Japan. The data are summarized into the frequency table with respect to gender 
and age. The age groups are < 20, 20 < age 30≤ , 30 < age 40≤ , 40 < age , and > 50≤
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50 years old. The comparison of carrier proportions of males and females under 20 
years old is made with a two-sided statistical test and for the other groups one-
sided tests are carried out. The preset statistical analysis shows that the carrier 
proportion of girls is less than that that of boys. It implies that in HTLV-I the 
mother-to-child transmission probability of females is less than that of males. 
According to the present findings, it follows that the female’s innate protection 
power against HTLV-I is stronger than that of males, and the conclusion may 
become a valid proposition for general human virus. 
 
Human T-cell Leukemia Virus Type I (HTLV-I) is a retrovirus that causes Adult 
T-cell Leukemia (ATL) and myelopathy/tropical paraparesis1-4. The carriers of this 
virus live on the Japanese Islands, the African Continent, in South America, the 
Caribbean Islands, Australia, and elsewhere5-8. In Japan, about one percent of the people 
are carriers, and fifty percents of these carriers live on Kyushu and Okinawa Islands3,4,9. 
In Japan, nationwide epidemiological studies have been made10-12. From 
epidemiological studies of HTLV-I infection, the following infection routes are 
established as the main routes4,6,13,14: (i) from infected mothers to their newborn babies 
via the mother's milk; (ii) from infected males (husbands) to susceptible females (their 
wives) through frequent sexual intercourse; and (iii) from infected females (wives) to 
males (husbands). Other minor transmission routes seem to be the intrauterine mother-
to-child transmission and the transmission via saliva15,16.  
 For detecting HTLV-I carriers, serological assays, e.g. the indirect 
immunofluorescence method (IF), enzyme-linked immunosorbent assay (ELISA) and 
gelatin particle agglutination method (PA), are usually used to diagnose HTLV-I 
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carriers. In Japan, IF was used for blood donor data by 1994; however a detection of 
HTLV-I carriers with only this method is insufficient for screening antibodies to 
HTLV-I-associated antigens17,18. In Japan, since 1995 three methods, i.e. IF, ELISA and 
PA, have been simultaneously employed to screen the antibody to HTLV-I more 
precisely. As far as these tests, the results are incomplete and the HTLV-I prevalence is 
underestimated with the usual serological assays19. It was reported that there was a 
HTLV-I seronegative and infected South Indian patient with chronic spastic 
paraparesis20, and seronegative rat models with HTLV-I infection were also 
experimentally established21-23. Thus, testing for Tax sequences and antibodies to its 
gene product, i.e. the polymerase chain reaction (PCR) method is needed for screening 
HTLV-I carriers in blood transfusion19,24,25. By using the PCR method, HTLV-I 
provirus was detected from seronegative Chilean patients with tropical spastic 
paraparesis26, and defective HTLV-I provirus was also derived from some seronegative 
Chilean patients with the disease27. In an HTLV-I endemic area in Japan, i.e. Tushima, 
209 healthy adults were examined for HTLV-I provirus by PCR and anti-HTLV-I 
antibodies by PA, ELISA, and IF; however none of the 133 seronegative subjects, i.e. 
seropositive subjects were 76, reacted positively on PCR. Hence, seronegative HTLV-I 
carriers are considered to be rare in Japan28. 
 In considering HTLV-I infection, the mother-to-child transmission probability is 
assumed to be the same between males and females, i.e. the innate immunity or bio-
protection powers of males and females are equivalent (e.g. 5, 14, 29). Doubtless the 
assumption has been employed since the virus was detected. In this paper, through 
statistical analysis of blood donor data in Oita prefecture, Japan, we derive a conclusion 
that the innate bio-protection power of females against HTLV-I may be stronger than 
that of males. 
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Summary of Blood Donor Data of HTLV-I in 1995 to 1998 
Table 1 shows the ‘blood donor data in 1995 to 1998’ provided by Japan Red Cross 
Society of Oita. The data are summarized in subgroups according to donors' age. The 
data are random samples from not the natural population in Oita prefecture, Japan, but 
the blood donor population which is defined below. Recently, HTLV-I carriers have 
chances to be screened through the blood donation and blood tests. Especially, pregnant 
women are tested their blood in order to prevent the mother-to-child transmission. In 
Japan, pregnant women infected with HTLV-I have recommended not to feed their 
babies on mother's milk since 1985. From this measure, carriers of infants are 
decreasing every year30,31; however blood donors in Table 1 is not affected from this 
medical intervention, because ages of blood donors in Japan are greater or equal to 
fifteen years old and the data were obtained in 1995 to 1998. Thus, AG1 can be viewed 
as a population without the screening effect, i.e. a natural population. The effect of 
screening on AG2 and AG3 of females is very strong, because the majority of the 
reproductive population in Japan is in the age groups and HTLV-I infection is informed 
to pregnant women concerned. If a pregnant woman is found to be a HTLV-I carrier, 
her husband may also have his blood examined in most cases. From this, the screening 
effect on males in AG2 and AG3 is also strong. From 1999 the carriers detected in blood 
donors are informed the HTLV-I infection; however the screening effect did not affect 
the data in Figure 1. Hence, the carrier proportion in blood donors is decreasing every 
year. A population from which a part of HTLV-I carriers were screened is referred to as 
a blood donor population (Fig. 1). The data in Table 1 are regarded as random samples 
from the blood donor population in each year, i.e. repeated measurement data. The 
estimated carrier proportions in age groups are illustrated in Figures 2 to 6. In AG1, the 
carrier proportions of boys are higher than those of girls in all four years. From this, the 
mother-to-child transmission probability of boys may be higher than that of girls. By 
using the HTLV-I carrier data of healthy residents of Okinawa, Japan, in periods 1968-
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1970, 1981-1984, and 1996-1999, Kashiwagi et al31 reported that there was no 
significant difference between boys and girls less than 20 years old. However, the data 
are small in considering the HTLV-I prevalence of children, i.e. 4 of 106 in boys and 5 
of 90 in girls in 1968-1970; 2 of 209 in boys and 5 of 204 in girls in 1981-1984; and 1 
of 522 in boys and 0 of 417 in girls in 1996-1999 are carriers. The prevalence of HTLV-
I carriers is small, i.e. about 1% to 5%, so large sample data are needed to derive more 
precise results. As shown in Table 1, the sizes of blood donor data are large, so a more 
powerful test for comparing the HTLV-I carrier proportions of males and females can 
be made with the data. The reverse process in carrier proportions of males and females 
with age may be illustrated in Figures 2 to 6. Moreover, a screening effect on carrier 
proportions may be shown in the Figures. 
 
Statistical analysis in carrier proportions 
Let )(),( taMπ  be the proportion of males who are infected in AGa at year t and 
let )(),( taFπ be the proportion of females who are infected in AGa at year t (t = 
1995,1996,1997,1998; a = 1,2,3,4,5). In testing the differences with respect to carrier 
proportions between males and females in 5 age groups, the following null and 
alternative hypotheses are employed: 
    H(1,0): )()( )1,()1,( tt FM ππ = ; H(1,1): )()( )1,()1,( tt FM ππ ≠ , 
H(a,0): )()( ),(),( tt aFaM ππ = ; H(a,1): )()( ),(),( tt aFaM ππ < , a = 2,3,4,5. 
For level of significance 05.0=α , the results are shown in Table 2. According to the 
results, the carrier proportion of males is higher than that of females under twenty. 
Since any medical intervention effects may be negligible in the age group, it can be 
concluded that the mother-to-child transmission probability of newborn baby boys is 
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higher than that of girls. This is a new finding obtained in this study. It may be 
remarkable, because as mentioned above the mother-to-child transmission probability 
has been assumed the same between boys and girls. The other results in Table 2 support 
the usual finding that the male-to-female transmission rate is higher than the female-to-
male transmission one. 
 
Discussion 
Although it has been thought that there is no difference in HTLV-I infection between 
boys and girls under twenty years old, from Figure 2 one may doubt whether it stands to 
reason. From the above statistical analysis, the HTLV-I carrier proportion of boys was 
significantly greater than that of girls under twenty, i.e. AG1. The HTLV-I infection in 
AG1 depends on the mother-to-child transmission by postnatal breast-feeding16. 
Through the reproductive population, the infection proportions are reversed between 
males and females. It follows that in the sexual transmission the female is more easily 
infected than the male; however the infection depends on the transmission routes. On 
the other hand, the present study has shown that the baby girl has a lower probability 
than the baby boy in mother-to-child transmission. The route of mother-to-child 
transmission is the same for baby boys and girls. The existence of window period of 
HTLV-I infection was reported32; however, seronegative HTLV-I carriers in Japanese 
healthy residents are rare28. In a follow-up study in Japan, none of 21 seronegative 
children born to seropositive mothers was seroconverted, and the HTLV-I provirus was 
not detected with PCR33. Hence, it follows that there are cases where invasions of 
HTLV-I through breast-feeding are completely defended without acquiring the 
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immunity against the virus and that the innate bio-protection power of females against 
HTLV-I is superior to that of males. 
   According to sex hormones the immunity of women may be stronger than that of men; 
however the present result has been derived from the mother-to-child transmission 
through breast-feeding and it does not depend on sex hormones. Thus, it may reach a 
valid conclusion that the female’s innate bio-protection power against human virus is 
stronger than that of males. By analyzing the difference between the ‘innate bio-
protection systems against human virus’ of males and females, a new protection 
measure against human virus may be developed. Experimental studies with animal 
models and epidemiological approaches with respect to human virus are required to 
explain and prove the proposition. 
 
Methods  
Let and be the numbers of male blood donors and HTLV-I infected 
males sampled from AG
)(),( tN aM )(),( tn aM
a at year t, respectively; and let and be those for 
females in AG
)(),( tN aF )(),( tn aF
a at year t, respectively. The maximum likelihood estimates of infection 
proportions are given by 
)(
)(
),( ),(
),()(ˆ tN
tn
aM aM
aMt =π , )( )(),( ),( ),()(ˆ tN tnaF aF aFt =π  (a = 1,2,3,4,5; t = 1995,1996,1997,1998).  
From the central limit theorem, the above statistics are independent and asymptotically 
distributed according to normal distributions with means )(),( taMπ and variances 
( )
)(
)(ˆ1)(ˆ2
),( ),(
),(),()(ˆ tN
tt
aM aM
aMaMt ππσ −= for males and with )(),( taFπ and ( ))( )(ˆ1)(ˆ2),( ),( ),(),()(ˆ tN ttaF aF aFaFt ππσ −=  
for females, respectively. The differences between carrier proportions of males and 
females in age groups are tested. The test statistics used are 
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2
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2
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1998
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)(ˆ)(ˆ
)(ˆ)(ˆ
t aFaM
t aFaM
a
tt
tt
Z
σσ
ππ
  (a = 1,2,…,5).                             (1) 
The above statistics are asymptotically distributed according to the standard normal 
distribution under the null hypotheses, i.e. H(a,0): 5,...,2,1 ),()( ),(),( == att aFaM ππ . 
Statistics (1) are used for testing the differences with respect to carrier proportions 
between males and females in 5 age groups.  
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Table 1. Blood Donor Data in 1995 to 1998 in Oita Prefecture, Japan 
           year                             1995                                     1996 
         gender                  male             female             male              female   
      AG1 [15,20)*   44 (3852)**   38 (5135)       31 (3914)        27 (5459) 
AG2 [20,30)     66 (9935)        69 (8860)       75 (10606)      72 (9636) 
AG3 [30,40)   125 (9759)        77 (3955)       140 (9891)      73 (4307) 
      AG4 [40,50)   248 (10016)     143 (3697)      248 (10858)   136 (3965) 
      AG5 [50,60)   168 (6374)       156 (3084)      199 (6620)     160 (3135) 
           year                           1997                                     1998 
       gender                  male         female                  male            female     
      AG1 [15,20)     30 (3615)     24 (4781)          23 (2813)       21 (4245) 
AG2 [20,30)     79 (10708)    58 (9638)         73 (10718)     78 (10470) 
AG3 [30,40)   115 (10349)    69 (4646)       112 (10365)     46 (5117) 
AG4 [40,50)   229 (11100)   127 (4087)      194 (10530)    126 (3950)  
AG5 [50,60)   200 (7224)    140 (3449)       218 (7610)      136 (3570) 
*) [a,b) implies ages from a to b years old. 
**) The numbers in parentheses are numbers of donors. 
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      Table 2. Comparison of carrier proportions of males and females 
              in age groups 
   Age Group      AG1        AG2         AG3          AG4        AG5  
   Z Statistic             879.3 555.0− 080.2−    776.8−     488.8−  
     P val.           0.000      0.289       0.0188     0.000       0.000 
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Figure 1. Screening Processes of HTLV-I Carriers. The arrow “→” implies aging, and 
the arrow “     ” the screening effect. 
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Figure 2. Changes of Carrier Proportions of Males and Females in AG1
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Figure 3. Changes of Carrier Proportions of Males and Females in AG2
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Figure 4. Changes of Carrier Proportions of Males and Females in AG3
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Figure 5. Changes of Carrier Proportions of Males and Females in AG4
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Figure 6. Changes of Carrier Proportions of Males and Females in AG5
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